X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Facilities & Operation

iMedrix Announces General Availability of KardioScreen, a CE certified, Connected ECG Device for Universal Use

Content Team by Content Team
17th January 2018
in Facilities & Operation, Press Statements

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

iMedrix, a Silicon Valley and Bangalore-based mHealth start-up, announced the general availability of its product KardioScreen, a CE certified mobile/portable hospital grade digital ECG.

KardioScreen is the first truly mobile, connected ECG solution that can be applied universally: field screening, point of care, ambulance, Cardiac ICU and at-home monitoring. The patent-pending KardioScreen solution comprises of a hospital grade mobile ECG device and mobility software suite of AI assisted solutions for doctors, ambulances and hospitals. KardioScreen can be used in both, snapshot short term ECG (30s) and extended observation/monitoring modes in 6 or 12 lead configuration.

KardioScreen is being used at a number of leading hospitals in Asia in a variety of use cases. An ECG taken from KardioScreen can be analyzed by a live/remote physician and AI engines in seconds. Further, the simple, deskilled use model and ability to record ECGs quickly, has been a major factor in the adoption of this solution for population screening.

Multiple layers of algorithmic and analytics solutions are added to KardioScreen to help physicians with actionable insights. This also enables a truly mobile, digital health architecture where third party devices and applications can fit in, acting as a base for Software as a Medical Device applications.

“We are pleased to introduce the world’s first end-to-end connected solution that brings mobility to cardiac care,” said Srikanth Jadcherla, CEO of iMedrix, “KardioScreen brings a deep IoT architecture to clinical use.”

“Cardiac diseases are at epidemic levels and burgeoning with every year. Early detection and prevention is the need of the hour. In this context, mobile medical solutions such as iMedrix’s KardioScreen could help patients get screened or monitored anywhere, in an affordable manner. 100s of millions of people will benefit from such mobile cardiac screenings, saving many lives by timely intervention. In the process, we are bound to learn a lot and gain new insights,” said Dr. Nagraj Desai, Distinguished Cardiologist.

KardioScreen is offered on subscription basis in Asia. With the obtainment of CE certification, iMedrix is now looking to enter markets in Europe.

About iMedrix
iMedrix is a Mobile Health (mHealth) start-up based in Silicon Valley and Bangalore. iMedrix is developing IoT mobile Health solutions starting with mobile cardiology.

For more information, visit: http://www.imedrix.com

Media Contact:
Nagesh Rangappan
CTO
+91-9611103647
nagesh.r@imedrix.com

Srikanth Jadcherla (Sree)
CEO
+1-408-637-1881
srikanth.j@imedrix.com

Previous Post

Vantage Cancer Care Network Collaborates with Alliance Cancer Specialists, PC, to Expand the Delivery of High-Quality Cancer Care across Philadelphia

Next Post

FuturaGene’s exclusive license for RNAi technology in Eucalyptus enhanced by grant of patent in Brazil

Related Posts

API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
API Manufacturing Facility
Americas

Lilly to Build $6.5B API Manufacturing Facility in Houston

25th September 2025
Merck and Siemens
Drug Development

Merck and Siemens to Accelerate AI Driven Drug Development

24th September 2025
Scottish Pharma Sector
Europe

ABPI Launches Manifesto to Advance Scottish Pharma Sector

23rd September 2025
Automating Experimental Design with Generative AI in Pharma
Facilities & Operation

Automating Experimental Design with Generative AI in Pharma

20th September 2025
Next Post

FuturaGene’s exclusive license for RNAi technology in Eucalyptus enhanced by grant of patent in Brazil

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In